Growth factor based therapies and intestinal disease: Is glucagon-like peptide-2 the new way forward?
2009
Yazbek, R. | Howarth, G. | Abbott, C.
Copyright © 2009 Published by Elsevier Ltd.
Afficher plus [+] Moins [-]Inflammatory bowel disease (IBD) is a chronic, debilitating disease associated with severe damage to the intestinal mucosa. Glucagon-like peptide-2 (GLP-2) is a potent and specific gastrointestinal growth factor that is demonstrating therapeutic potential for the prevention or treatment of an expanding number of intestinal diseases, including short bowel syndrome (SBS), small bowel enteritis and IBD. The biological activity of GLP-2 is limited due to proteolytic inactivation by the protease dipeptidyl peptidase (DP)IV. Inhibitors of DPIV activity may represent a novel strategy to prolong the growth promoting actions of GLP-2. This review outlines evidence for the clinical application of GLP-2, its degradation resistant analogue, Teduglutide, and novel DPIV inhibitors in efficacy studies utilizing pre-clinical models of intestinal damage, in particular IBD.
Afficher plus [+] Moins [-]Roger Yazbeck, Gordon S. Howarth and Catherine A. Abbott
Afficher plus [+] Moins [-]http://www.elsevier.com/wps/find/journaldescription.cws_home/868/description#description
Afficher plus [+] Moins [-]Informations bibliographiques
Cette notice bibliographique a été fournie par University of Adelaide
Découvrez la collection de ce fournisseur de données dans AGRIS